Barclays analyst Andrew Mok raised the firm’s price target on Centene (CNC) to $44 from $35 and keeps an Equal Weight rating on the shares following the Q3 report. The company’s 2025 Medicaid margins are ending the year higher, helped by actions in Florida and New York, but Centene no longer expects 2026 margin improvement, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNC: